79 related articles for article (PubMed ID: 9027619)
1. Smart Diagnostics: Combining Artificial Intelligence and In Vitro Diagnostics.
McRae MP; Rajsri KS; Alcorn TM; McDevitt JT
Sensors (Basel); 2022 Aug; 22(17):. PubMed ID: 36080827
[TBL] [Abstract][Full Text] [Related]
2. Nuclear F-actin Cytology in Oral Epithelial Dysplasia and Oral Squamous Cell Carcinoma.
McRae MP; Kerr AR; Janal MN; Thornhill MH; Redding SW; Vigneswaran N; Kang SK; Niederman R; Christodoulides NJ; Trochesset DA; Murdoch C; Dapkins I; Bouquot J; Modak SS; Simmons GW; McDevitt JT
J Dent Res; 2021 May; 100(5):479-486. PubMed ID: 33179547
[TBL] [Abstract][Full Text] [Related]
3. Cell-type specificity of β-actin expression and its clinicopathological correlation in gastric adenocarcinoma.
Khan SA; Tyagi M; Sharma AK; Barreto SG; Sirohi B; Ramadwar M; Shrikhande SV; Gupta S
World J Gastroenterol; 2014 Sep; 20(34):12202-11. PubMed ID: 25232253
[TBL] [Abstract][Full Text] [Related]
4. [Non-invasive urinary diagnosis of bladder cancer. What do we know?].
Kausch I; Böhle A
Urologe A; 2003 Jul; 42(7):912-21. PubMed ID: 12898034
[TBL] [Abstract][Full Text] [Related]
5. Opposing roles of the extracellular signal-regulated kinase and p38 mitogen-activated protein kinase cascades in Ras-mediated downregulation of tropomyosin.
Shields JM; Mehta H; Pruitt K; Der CJ
Mol Cell Biol; 2002 Apr; 22(7):2304-17. PubMed ID: 11884615
[TBL] [Abstract][Full Text] [Related]
6. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
Greenwald P
J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
[TBL] [Abstract][Full Text] [Related]
7. Cellular F-actin levels as a marker for cellular transformation: correlation with bladder cancer risk.
Rao JY; Hemstreet GP; Hurst RE; Bonner RB; Min KW; Jones PL
Cancer Res; 1991 Jun; 51(11):2762-7. PubMed ID: 2032215
[TBL] [Abstract][Full Text] [Related]
8. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the DD23 tumor-associated antigen for bladder cancer detection and recurrence monitoring. Marker Network for Bladder Cancer.
Bonner RB; Liebert M; Hurst RE; Grossman HB; Bane BL; Hemstreet GP
Cancer Epidemiol Biomarkers Prev; 1996 Dec; 5(12):971-8. PubMed ID: 8959319
[TBL] [Abstract][Full Text] [Related]
10. G-actin as a risk factor and modulatable endpoint for cancer chemoprevention trials.
Hemstreet GP; Rao J; Hurst RE; Bonner RB; Waliszewski P; Grossman HB; Liebert M; Bane BL
J Cell Biochem Suppl; 1996; 25():197-204. PubMed ID: 9027619
[TBL] [Abstract][Full Text] [Related]
11. Risk biomarkers and current strategies for cancer chemoprevention.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
